Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company focused on developing new cancer medicines, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management team will engage in a fireside chat on Wednesday, September 18 at 3:40 pm EDT.
Interested parties can access a live webcast of the discussion through the 'Events & Presentations' section of Verastem's website. For those unable to attend live, a replay of the webcast will be available on the company's website for approximately 90 days following the presentation.
Verastem Oncology (Nasdaq: VSTM), un'azienda biofarmaceutica focalizzata sullo sviluppo di nuovi farmaci contro il cancro, ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale Cantor 2024. Il team di gestione dell'azienda parteciperà a un fireside chat mercoledì, 18 settembre alle 15:40 EDT.
Le parti interessate possono accedere a un webcast dal vivo della discussione attraverso la sezione 'Eventi e Presentazioni' del sito web di Verastem. Per coloro che non possono partecipare dal vivo, sarà disponibile un ripasso del webcast sul sito dell'azienda per circa 90 giorni dopo la presentazione.
Verastem Oncology (Nasdaq: VSTM), una compañía biofarmacéutica centrada en el desarrollo de nuevos medicamentos contra el cáncer, ha anunciado su participación en la Conferencia Global de Salud Cantor 2024. El equipo de gestión de la empresa participará en un fireside chat el miércoles 18 de septiembre a las 3:40 p. m. EDT.
Las partes interesadas pueden acceder a un webcast en vivo de la discusión a través de la sección 'Eventos y Presentaciones' del sitio web de Verastem. Para aquellos que no puedan asistir en vivo, un replay del webcast estará disponible en el sitio web de la empresa durante aproximadamente 90 días después de la presentación.
Verastem Oncology (Nasdaq: VSTM)는 새로운 항암제를 개발하는 데 집중하는 생물의약품 회사로, 2024 캔토르 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 관리 팀은 2024년 9월 18일 수요일 오후 3시 40분 EDT에 화재측 대화를 진행할 예정입니다.
관심 있는 분들은 Verastem 웹사이트의 '이벤트 및 발표' 섹션을 통해 논의에 대한 실시간 웹캐스트에 접근할 수 있습니다. 실시간으로 참석할 수 없는 분들을 위해, 발표 후 약 90일 동안 회사 웹사이트에서 재방송이 제공될 예정입니다.
Verastem Oncology (Nasdaq: VSTM), une entreprise biopharmaceutique axée sur le développement de nouveaux médicaments contre le cancer, a annoncé sa participation à la Conférence Mondiale de Santé Cantor 2024. L'équipe de direction de l'entreprise participera à une discussion informelle le mercredi 18 septembre à 15h40 EDT.
Les parties intéressées peuvent accéder à un webinaire en direct de la discussion via la section 'Événements et Présentations' du site web de Verastem. Pour ceux qui ne peuvent pas assister en direct, un rediffusion du webinaire sera disponible sur le site de l'entreprise pendant environ 90 jours suivant la présentation.
Verastem Oncology (Nasdaq: VSTM), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuer Krebsmedikamente konzentriert, hat seine Teilnahme an der 2024 Cantor Global Healthcare Conference bekannt gegeben. Das Management-Team des Unternehmens wird an einem Fireside Chat am Mittwoch, den 18. September um 15:40 Uhr EDT teilnehmen.
Interessierte Parteien können über den Bereich 'Veranstaltungen & Präsentationen' der Verastem-Website auf ein Live-Webcast der Diskussion zugreifen. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung des Webcasts etwa 90 Tage nach der Präsentation auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors & Media section of the company’s website at www.verastem.com. A replay of the webcast will be archived on the website for approximately 90 days following the presentation.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on RAS/MAPK-driven cancers, specifically novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. For more information, please visit www.verastem.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910342603/en/
For Investor and Media Inquiries:
Julissa Viana
Vice President, Corporate Communications and Investor Relations
investors@verastem.com or
media@verastem.com
Source: Verastem Oncology
FAQ
When is Verastem Oncology (VSTM) presenting at the 2024 Cantor Global Healthcare Conference?
How can I watch Verastem Oncology's (VSTM) presentation at the 2024 Cantor Global Healthcare Conference?
Will there be a replay available of Verastem Oncology's (VSTM) 2024 Cantor Global Healthcare Conference presentation?
What type of presentation will Verastem Oncology (VSTM) give at the 2024 Cantor Global Healthcare Conference?
